Xencor (XNCR) Competitors $8.37 +0.04 (+0.48%) Closing price 04:00 PM EasternExtended Trading$8.55 +0.18 (+2.16%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. CNTA, DNLI, IBRX, AGIO, IDYA, OCUL, HRMY, IRON, CGON, and RXRXShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Harmony Biosciences (HRMY), Disc Medicine (IRON), CG Oncology (CGON), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Its Competitors Centessa Pharmaceuticals Denali Therapeutics ImmunityBio Agios Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Harmony Biosciences Disc Medicine CG Oncology Recursion Pharmaceuticals Centessa Pharmaceuticals (NASDAQ:CNTA) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends. Which has better earnings & valuation, CNTA or XNCR? Xencor has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M308.68-$235.76M-$1.79-8.82Xencor$110.49M5.40-$232.62M-$2.40-3.49 Do institutionals & insiders believe in CNTA or XNCR? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is CNTA or XNCR more profitable? Centessa Pharmaceuticals has a net margin of 0.00% compared to Xencor's net margin of -121.52%. Xencor's return on equity of -25.75% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -40.39% -29.87% Xencor -121.52%-25.75%-18.19% Does the media refer more to CNTA or XNCR? In the previous week, Xencor had 3 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 19 mentions for Xencor and 16 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.09 beat Xencor's score of 0.87 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 10 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer CNTA or XNCR? Centessa Pharmaceuticals presently has a consensus target price of $31.45, indicating a potential upside of 99.21%. Xencor has a consensus target price of $22.25, indicating a potential upside of 165.83%. Given Xencor's higher probable upside, analysts plainly believe Xencor is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 3.08Xencor 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more risk & volatility, CNTA or XNCR? Centessa Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. SummaryCentessa Pharmaceuticals beats Xencor on 10 of the 17 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$594.12M$2.55B$5.76B$9.85BDividend YieldN/A49.35%6.71%4.51%P/E Ratio-3.495.4559.1122.53Price / Sales5.40714.55547.00119.09Price / CashN/A169.7737.0558.92Price / Book0.875.3910.916.06Net Income-$232.62M$32.95M$3.29B$266.28M7 Day Performance3.98%0.48%0.01%-0.76%1 Month Performance5.28%6.61%7.06%3.83%1 Year Performance-49.67%-0.50%50.09%24.39% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor3.8192 of 5 stars$8.37+0.5%$22.25+165.8%-50.8%$594.12M$110.49M-3.49280News CoverageAnalyst ForecastCNTACentessa Pharmaceuticals3.5162 of 5 stars$16.79+1.4%$31.50+87.6%+17.9%$2.25B$6.85M-9.38200News CoveragePositive NewsAnalyst ForecastDNLIDenali Therapeutics4.351 of 5 stars$15.27-2.4%$33.62+120.1%-39.1%$2.23B$330.53M-5.45430Positive NewsIBRXImmunityBio2.5054 of 5 stars$2.34+0.4%$10.75+359.4%-35.9%$2.21B$14.74M-4.87590AGIOAgios Pharmaceuticals4.3893 of 5 stars$37.71-1.2%$56.33+49.4%-9.2%$2.19B$36.50M3.43390News CoveragePositive NewsAnalyst ForecastOptions VolumeGap DownIDYAIDEAYA Biosciences4.4336 of 5 stars$24.55-1.5%$47.10+91.9%-32.4%$2.15B$7M-6.4880Trending NewsAnalyst ForecastAnalyst RevisionOCULOcular Therapeutix3.438 of 5 stars$12.21-2.5%$17.20+40.9%+55.0%$2.12B$63.72M-9.54230HRMYHarmony Biosciences4.3059 of 5 stars$36.89-2.8%$51.00+38.2%+3.2%$2.12B$714.73M11.90200News CoveragePositive NewsIRONDisc Medicine3.3184 of 5 stars$59.650.0%$98.30+64.8%+24.1%$2.07BN/A-13.3430Positive NewsCGONCG Oncology3.0428 of 5 stars$26.82+0.4%$54.30+102.5%-18.9%$2.04B$1.14M-15.1561News CoveragePositive NewsAnalyst UpgradeInsider TradeRXRXRecursion Pharmaceuticals2.303 of 5 stars$4.70-3.3%$7.00+48.9%-23.7%$2.04B$58.84M-2.64400 Related Companies and Tools Related Companies Centessa Pharmaceuticals Alternatives Denali Therapeutics Alternatives ImmunityBio Alternatives Agios Pharmaceuticals Alternatives IDEAYA Biosciences Alternatives Ocular Therapeutix Alternatives Harmony Biosciences Alternatives Disc Medicine Alternatives CG Oncology Alternatives Recursion Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XNCR Stock Alerts